Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nutritia GmbH, 91052 Erlangen, Germany | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The LIPCAL-ALS study (NCT02306590) has provided preliminary evidence that a high-caloric nutrition might prolong survival in fast-progressing ALS patients. Since increasing the amount of calories of the intervention might possibly increase the beneficial effect, the investigators seek to investigate whether an ultra-high caloric diet (UHCD), featuring the double amount of calories compared to LIPCAL-ALS, will be well tolerated by ALS patients and may serve as an intervention for a potential LIPCALII study. For this purpose, the investigators will compare two different UHCDs (one fat-rich and one carbohydrate-rich) with regard to safety and tolerability over a time frame of 4 weeks. A third group will receive the original diet from LIPCAL, and a fourth group will receive no intervention (control group).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| high-caloric fatty diet | Active Comparator | intake of 405 kcal (45g fat) per day in addition to normal food intake |
|
| ultra-high-caloric fatty diet | Experimental | intake of 810 kcal (90g fat) per day in addition to normal food intake |
|
| ultra-high-caloric carbohydrate-rich diet | Experimental | intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake |
|
| control | No Intervention | normal food intake (no intervention) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| high-caloric fatty diet | Dietary Supplement | see arm/group description |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events and Serious Adverse Events | Incidence of Adverse Events and Serious Adverse Events | 4 weeks |
| Laboratory values | Incidence of abnormalities in clinical laboratory assessments, vital signs and physical examinations | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Appetite | Change of Appetite-Score (Council of Nutrition appetite questionnaire, CNAQ) compared to baseline; values 8-40; higher values mean better appetite | 2 weeks; 4 weeks |
| Eating Habits | Change in eating habits as evaluated by a standardized questionnaire (Ulmer eating habits questionnaire); descriptive information and evaluation; no overall score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Johannes Dorst, PD Dr. | University of Ulm | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Ulm, Department of Neurology | Ulm | Baden-Wurttemberg | 89081 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26121170 | Background | Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J; WFN Research Group On ALS/MND. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-2. doi: 10.3109/21678421.2015.1049183. Epub 2015 Jun 29. No abstract available. |
Not provided
Not provided
Data will be available beginning 3 months and ending 5 years following article publication. Data will be shard with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal. Proposals should be directed to johannes.dorst@uni-ulm.de; to gain access, data requestors will need to sign a data acess agreement. The study protocol will be available for 5 years at htpps://www.uniklinik-ulm.de/neurologie.html.
3 month after publication until 5 years after publication
Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal. Proposals should be directed to johannes.dorst@uni-ulm.de; to gain access, data requestors will need to sign a data acess agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
| ultra-high-caloric fatty diet |
| Dietary Supplement |
see arm/group description |
|
| ultra-high-caloric carbohydrate-rich diet | Dietary Supplement | see arm/group description |
|
| 2 weeks; 4 weeks |
| Taste of Intervention | taste of intervention (visual analogous scale); values 1-9, higher values mean better taste | 2 weeks; 4 weeks |
| Body Weight | change of body weight compared to baseline | 2 weeks; 4 weeks |
| Biomarkers | change of neurofilament light chains (NfL) in serum | 4 weeks |
| Adverse Events and Serious Adverse Events | Incidence of Adverse Events and Serious Adverse Events (evaluation via phone call 2 weeks after intervention was finished) | 6 weeks |
| ALSFRS-R | change of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) compared to baseline; values 0-48; higher values mean less impairment | 4 weeks |
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided